Core Insights - Prenetics is positioning itself as a unique player in the supplement industry by integrating a Bitcoin treasury strategy alongside its core business operations [2][4]. - The company aims to achieve over $100 million in annual recurring revenue within a year of launching its IM8 brand, highlighting its rapid growth and innovative business model [3]. Financial Overview - Prenetics currently holds 248.42 BTC, with a net asset value (NAV) of approximately $28 million and an average purchase price of about $108,600 per BTC [5][1]. - The company has $63.5 million in cash, which includes various current assets such as cash equivalents and trade receivables [1][7]. Strategic Initiatives - Prenetics initiated its Bitcoin treasury strategy in June 2025, committing a significant portion of its balance sheet to Bitcoin and planning to acquire one Bitcoin daily [4][6]. - The company has already purchased 187.42 BTC for around $20 million at an average price of $106,712 per BTC, demonstrating its commitment to this strategy [5]. Market Position - The IM8 brand is recognized as one of the fastest-growing supplement brands, reflecting Prenetics' innovative approach at the intersection of health and wealth [2][3]. - Prenetics is set to present at Token 2049, a major crypto and blockchain conference, further establishing its presence in the digital asset space [1][9].

Core Insights - Nature's Sunshine Products, Inc. reported a strong start to 2025 with first quarter revenue of $113 million, reflecting a 5% increase on a constant currency basis and a 20% rise in adjusted EBITDA to $11 million compared to the previous year [3][8][6] Financial Performance - Net sales increased by 2% to $113.2 million from $111.0 million in the same quarter last year, with a 5% increase when excluding foreign exchange impacts [6][8] - Gross profit margin improved to 72.1% from 71.2% year-over-year, driven by price increases and effective cost-saving initiatives [6] - GAAP net income attributable to common shareholders rose 104% to $4.7 million, or $0.25 per diluted share, compared to $2.3 million, or $0.12 per diluted share, in the prior year [8][12] Segment Performance - Sales by region showed varied performance: - Asia: $48.7 million, up 5.3% (10.1% excluding currency impact) - Europe: $24.1 million, up 8.2% (8.6% excluding currency impact) - North America: $35.0 million, down 4.1% (3.7% excluding currency impact) - Latin America and Other: $5.5 million, down 8.2% (3.7% excluding currency impact) [4][30] Cost Management - Selling, general and administrative expenses (SG&A) decreased slightly to $40.6 million from $40.8 million, representing 35.8% of net sales compared to 36.7% in the prior year [9] - Operating income increased to $6.2 million, or 5.4% of net sales, compared to $4.6 million, or 4.2% of net sales, in the previous year [10] Capital Allocation - The board of directors authorized a share repurchase program of up to $25 million, supplementing the remaining $8.3 million from a previous authorization [2][4] Outlook - The company expects full-year 2025 net sales to range between $445 million and $470 million, with adjusted EBITDA projected between $38 million and $44 million [15]